FABTECH share price, P/E, ROE & financials

Fabtech Technologies (FABTECH) had a P/E of 15.5× on 6 Nov 2026, below the industry P/E of 26.0×, and the shares are 49% below their 52-week high. Sales and net profit grew 28% and 21% a year over 3 years; its ROCE of 12% is the second-lowest among its 5 Health Information Services peers, though net profit is above operating profit, which points to a one-off gain. Debt is 0.17× equity, and its dividend yield is 0.5%. It is a small-cap company with a market cap of ₹587 Cr, ranked 4th of 6 Health Information Services companies by market cap; the shares fell 43% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Sep 2026.How we calculate this

past year

Open: ₹132.35
Day high: ₹134.17
Day low: ₹131.00
Prev. close: ₹134.37
Volume: 37.3K

Health check

4 fair · 1 to check

ReturnsIn line
−43.5% over a year, better than 2 of 5 peers.
Price tagDistorted
A one-off gain inflates profit, so P/E isn’t comparable right now.
GrowthSteady
Sales +28.3%, profit +20.8% a year over 3 years.
ProfitabilityAverage
ROCE 11.8% vs peer median 15.3%.
Balance sheetFair
Debt 0.17× equity, interest covered 11.4×, Piotroski 5 of 9.
Red flags4 to check
Quarterly profit down 46.5% on a year ago.

Compared with 5 industry peers. Computed from reported figures. Educational, not a recommendation.

Health Information Services

5 listed peers. Screen the industry

Small cap

₹587 Cr, #4 of 6 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Sep 2026: sales ₹418 Cr · profit ₹49 Cr

Market cap: ₹587 Cr; Small cap
P/E: 15.5; Industry 26.0
Price to book: 1.21; Peers 4.37
Dividend yield: 0.45%
ROE: 12.9%; Peers 13.2%
ROCE: 11.8%; Peers 15.3%
Debt to equity: 0.17; Debt ₹70 Cr
EPS (TTM): ₹8.52; Face value ₹10
OPM (TTM): 6.5%; Net margin 11.7%
Sales growth: −24.2%; Latest quarter vs a year ago
Profit growth: −46.5%; Latest quarter vs a year ago
Price to sales: 1.40; EV/EBITDA 8.5

Risks to check

Quarterly profit down 46.5% on a year ago.
Quarterly sales down 24.2% on a year ago.
Net profit is above operating profit, so a one-off gain is likely flattering earnings.
49% below its 52-week high.

No standout strengths in the headline numbers.

Derived automatically from reported figures. Not a recommendation.

About Fabtech Technologies

Fabtech Technologies Limited operates as a biopharma engineering company that provides aseptic manufacturing facilities internationally. The company offers designing, engineering, procurement, installation, and testing of pharmaceutical equipment. It serves pharmaceuticals, biotech, and healthcare companies. The company was founded in 2001 and is based in Mumbai, India.

Headquarters: Mumbai
Employees: 186
Sector: Healthcare
ISIN: INE0HF201011
Website: fabtechnologies.com

Price range

52 weeks

₹115.10₹258.00

Today

₹131.00₹134.17

Avg volume (3M): 1 L
1-year return: minus 43.5%
From 52-week high: minus 48.8%

Peers · Health Information Services

Compare with peers Screen the whole industry

Company
IKSInventurus Knowledge Solutions	1,657.10	minus 5.70%	27,799	35.4	8.32	29.6%	28.2%	33.7%	45.7%	33.2%	0.00%	plus 5.4%
SAGILITYSagility	43.46	minus 0.78%	20,345	19.8	1.98	12.5%	10.7%	24.4%	19.5%	86.0%	0.69%	minus 15.1%
INDGNIndegene	609.75	minus 0.59%	14,684	35.9	4.37	15.3%	13.2%	16.5%	15.0%	14.7%	0.37%	plus 13.8%
FABTECHFabtech Technologies	131.98	minus 1.78%	587	15.5	1.21	11.8%	12.9%	2.4%	28.3%	20.8%	0.45%	minus 43.5%
TAKETAKE	12.57	plus 4.84%	186	32.2	6.10	15.4%	42.1%	−0.9%	−34.1%	–	0.00%	minus 49.8%
DEEPAIDeep Health AI India	1.64	0.00%	24	14.9	0.65	3.2%	3.1%	−457.4%	−17.9%	−3.4%	12.20%	minus 81.9%
Median of 5 peers	–	−0.59%	14,684	32.2	4.37	15.3%	13.2%	16.5%	15.0%	23.9%	0.37%	−15.1%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Sep 25	Dec 25	Mar 26	Jun 26	Sep 26
121	62.8	159	75	92.1
91	74.2	136	70.7	82
30.5	−11.5	22.2	4.2	10.1
25.1%	−18.3%	14.0%	5.7%	11.0%
3.2	7	9.8	3.1	5.5
1.1	0.9	0.9	0.9	1
1.3	1.3	1.3	1.3	1.3
–	–	–	–	8.4
31.3	−6.7	29.9	5.2	21.7
10.1%	15.1%	26.2%	19.5%	30.8%
28.1	−5.7	22.1	4.2	15
6.32	-1.56	5.75	0.95	3.38

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +28.3%
Profit CAGR 3Y: +20.8%
ROE: 12.9%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
194	226	322	409
–	+16.7%	+42.6%	+26.8%
171	191	281	372
22.6	35.6	41	36.8
11.7%	15.7%	12.7%	9.0%
9.8	3.9	4.3	19.3
2.6	1.9	1.7	4.6
1.9	2.1	2.6	5.3
–	0.2	19.5	2.1
27.9	35.8	60.4	48.3
22.1%	23.9%	23.1%	20.5%
21.7	27.2	46.5	38.4
–	+25.2%	+70.7%	minus 17.4%
–	–	10.45	10.00

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
2.8	2.9	32.4	44.5
86.2	129	141	375
35.4	12.7	83.8	69.6
89.5	125	170	201
214	269	427	691
3.6	5.6	56.5	54.9
10.1	0	–	23.8
11.9	73.5	21.2	224
188	190	349	388
214	269	427	691

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
−13.9	60.4	−36.1	0.5
1.9	−30	−20	−112
12	−12	36.3	190
−0	18.5	−19.9	77.8
−0.3	−1.2	−24.8	−4.7
−14.2	59.2	−60.9	−4.2
–	–	−4.9	–

Shareholding pattern

Source: NSE filings

NSE hasn’t returned a shareholding pattern for this company. Institutions hold about 1.2% (Yahoo estimate).

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you